Furmonertinib is an Oral, Irreversible, Highly BrainPenetrant Pan-EGFR Inhibitor with Activity Against Classical and Atypical EGFR Mutations

被引：0
|
作者：
Musib, L. [1 ]
Kowanetz, M. [1 ]
Li, Q. [2 ]
Luo, H. [2 ]
Hu, J. [2 ]
Lutzker, S. [1 ]
机构：
[1] ArriVent Biopharma, Newtown Sq, PA USA
[2] Allist Pharmaceut, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.11
引用
收藏
页码：E14 / E15
页数：2
相关论文
共 30 条
  • [21] CLINICAL ACTIVITY OF BIBW 2992, AN IRREVERSIBLE INHIBITOR OF EGFR/HER1 AND HER2 IN ADENOCARCINOMA OF THE LUNG WITH MUTATIONS IN THE KINASE DOMAIN OF HER2NEU
    De Greve, J.
    Decoster, L.
    De Mey, J.
    In 't Veld, P.
    Geers, C.
    Taton, M.
    Shahidi, M.
    Galdermans, D.
    Teugels, E.
    Schallier, D.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S90 - S91
  • [22] Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations
    Lopez, S.
    Bellone, S.
    Black, J. D.
    Schwab, C. L.
    English, D. P.
    Terranova, C.
    Schwartz, P. E.
    Rutherford, T. J.
    Angioli, R.
    Santin, A.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 144 - 144
  • [23] MP-412, a dual EGFR/HER2 tyrosine kinase inhibitor shows antitumor activity against both Erlotinib/Gefitinib-sensitive and resistant EGFR mutations in human lung cancer xenograft models
    Fujii, Akihiro
    Suzuki, Tsuyoshi
    Ohya, Jun-Ichi
    Nakamura, Hideo
    CANCER RESEARCH, 2006, 66 (08)
  • [24] Pre-clinical In Vitro and In Vivo Characterization of a Novel EGFR Sparing ErbB2 Inhibitor with Activity Against Oncogenic ErbB2 Mutations
    Chicarelli, M. J.
    Bouhana, K.
    Cable, L.
    Crow, M.
    Fell, B.
    Fischer, J.
    Fulton, J.
    Guarnieri, A.
    Jalluri, R.
    Robinson, J.
    Sullivan, F.
    Winski, S.
    Zhou, Y.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S81 - S81
  • [25] Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I
    Floc'h, Nicolas
    Lim, Sangbin
    Bickerton, Sue
    Ahmed, Afshan
    Orme, Jonathan
    Urosevic, Jelena
    Martin, Matthew J.
    Cross, Darren A. E.
    Cho, Byoung Chul
    Smith, Paul D.
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (11) : 2298 - 2307
  • [26] JIN-A02, a fourth-generation, highly effective tyrosine kinase inhibitor with intracranial activity, targeting EGFR C797S mutations in NSCLC
    Yun, M. R.
    Yu, M. R.
    Duggirala, K. B.
    Lee, K.
    Lim, S. M.
    Jo, A.
    Seah, E.
    Kim, C.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1010 - S1011
  • [27] Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models
    Cha, Mi Young
    Lee, Kwang-Ok
    Kim, Mira
    Song, Ji Yeon
    Lee, Kyu Hang
    Park, Jongmin
    Chae, Yun Jung
    Kim, Young Hoon
    Suh, Kwee Hyun
    Lee, Gwan Sun
    Park, Seung Bum
    Kim, Maeng Sup
    INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (10) : 2445 - 2454
  • [28] Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models
    Cha, Mi Young
    Lee, Kwang-Ok
    Kim, Young Hun
    Suh, Kwee Hyun
    Park, Seung Bum
    Kim, Maeng Sup
    Lee, Gwan Sun
    CANCER RESEARCH, 2011, 71
  • [29] OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models
    Libouban, Marion
    Jovcehva, Eleonora
    De lange, Desiree
    Janssens, Boudewijn
    Verhulst, Tinne
    Ogata, Souichi
    Wroblowski, Berthold
    Mevellec, Laurence
    Lu, Tianbao
    Clack, Glen
    Perera, Timothy
    CANCER RESEARCH, 2018, 78 (13)
  • [30] Integrating the pre-clinical pharmacokinetic, pharmacodynamics, and efficacy data for AZD9291, an oral, irreversible inhibitor of EGFR activating (EGFRm plus ) and resistant (EGFRm+/T790M) mutations and an active metabolite to predict the human pharmacokinetics and potential efficacious dose in patients.
    Ballard, Peter
    Ashton, Susan
    Cross, Darren
    Dimelow, Richard
    Yates, James
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
123